drugset / Trial / NCT06663748
ARX788 in HER2-positive Metastatic Breast Cancer Patients
NaSingle-groupOpen-labelTreatment
Summary
A phase 2 study of ARX788 given every 6 weeks in HER2-positive, metastatic breast cancer patients.
Timeline
- Start
- 2024-11-20
- Primary completion
- 2025-11-20
- Completion
- 2029-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ANVATABART OPADOTIN | Other / unclassified | 2.2 mg/kg | Intravenous |